Show simple item record

dc.creatorObradović, Milan M.
dc.creatorZafirović, Sonja
dc.creatorSoskić, Sanja S.
dc.creatorStanimirović, Julijana
dc.creatorTrpković, Andreja
dc.creatorJevremović, Danimir P.
dc.creatorIsenović, Esma R.
dc.date.accessioned2020-02-11T23:03:05Z
dc.date.available2020-02-11T23:03:05Z
dc.date.issued2019
dc.identifier.issn1381-6128
dc.identifier.urihttp://vinar.vin.bg.ac.rs/handle/123456789/8483
dc.description.abstractCardiovascular (CV) diseases are the most common health problems worldwide, with a permanent increase in incidence. Growing evidence underlines that insulin-like growth factor 1 (IGF-1) is a very important hormone responsible for normal CV system physiology. IGF-1 is an anabolic growth hormone, responsible for cell growth, differentiation, proliferation, and survival. Despite systemic effects, IGF-1 exerts a wide array of influences in the CV system affecting metabolic homeostasis, vasorelaxation, cardiac contractility and hypertrophy, autophagy, apoptosis, and antioxidative processes. The vasodilatory effect of IGF-1, is achieved through the regulation of the activity of endothelial nitric oxide synthase (eNOS) and, at least partly, through enhancing inducible NOS (iNOS) activity. Also, IGF-1 stimulates vascular relaxation through regulation of sodium/potassium-adenosine-triphosphatase. Numerous animal studies provided evidence of diverse influences of IGF-1 in the CV system such as vasorelaxation, anti-apoptotic and prosurvival effects. Human studies indicate that low serum levels of free or total IGF-1 contribute to an increased risk of CV and cerebrovascular disease. Large human trials aiming at finding clinical efficacy and outcome of IGF-1-related therapy are of great interest. We look forward to the development of new IGF 1 therapies with minor side effects. In this review, we discuss the latest literature data regarding the function of IGF-1 in the CV system in the physiological and pathophysiological conditions. © 2019 Bentham Science Publishers.en
dc.language.isoen
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173033/RS//
dc.rightsrestrictedAccess
dc.sourceCurrent Pharmaceutical Design
dc.subjectcardiovascular diseaseen
dc.subjectcardiovascular systemen
dc.subjectIGF-1en
dc.subjectvasodilatory effecten
dc.subjectanti-apoptotic effecten
dc.subjecttissue restructuring effectsen
dc.subjectanti-aging effectsen
dc.titleEffects of IGF-1 on the cardiovascular systemen
dc.typearticleen
dc.rights.licenseARR
dcterms.abstractИсеновиц, Е Р; Обрадовиц, М; Зафировиц, С; Соскиц, С; Станимировиц, Ј; Трпковиц, A; Јевремовиц, Д;
dc.rights.holder© 2019 Bentham Science Publishers
dc.citation.volume25
dc.citation.issue35
dc.citation.spage3715
dc.citation.epage3725
dc.identifier.wos000502328500003
dc.identifier.doi10.2174/1381612825666191106091507
dc.citation.rankM22
dc.identifier.pmid31692426
dc.type.versionpublishedVersion
dc.identifier.scopus2-s2.0-85076482879


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record